A5065276140- Chronic Lymphocytic Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Multiple Myeloma Research and Treatments
- Eosinophilic Disorders and Syndromes
- Hematopoietic Stem Cell Transplantation
- Acute Myeloid Leukemia Research
- Lymphoma Diagnosis and Treatment
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Platelet Disorders and Treatments
- Protein Degradation and Inhibitors
- Peptidase Inhibition and Analysis
- Blood groups and transfusion
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Complement system in diseases
- Cancer Treatment and Pharmacology
- CAR-T cell therapy research
- Immune Cell Function and Interaction
- Acute Lymphoblastic Leukemia research
- CNS Lymphoma Diagnosis and Treatment
- Blood disorders and treatments
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Autoimmune and Inflammatory Disorders Research
- Fungal Infections and Studies
- Vascular Tumors and Angiosarcomas
- Cardiac tumors and thrombi
Jikei University Kashiwa hospital
2015-2024
Jikei University School of Medicine
2011-2023
The Jikei University Hospital
2023
The University of Tokyo
1997-1998
Institute of Ismaili Studies
1998
Tokyo University of Science
1997
Hemophagocytic syndrome (HPS) presents with fever, pancytopenia, liver dysfunction and increase in hemophagocytic histiocytes various organs. Although there are two major classifications of HPS adults, malignant reactive histiocytosis, it is often very difficult to distinguish between these disorders. We analyzed the laboratory data patients evaluate prognostic factors. Of 34 patients, 14 survived, 20 died. The median age survivors was 29.6+/-11.5 yr significantly younger than those who died...
The purpose of this trial was to evaluate the efficacy 2-year consolidation therapy with nilotinib, at a dose 300 mg twice daily, for achieving treatment-free remission in chronic myeloid leukemia patients deep molecular response (BCR-ABL1IS ≤0.0032%). Successful defined as no confirmed loss response. We recruited 96 Japanese patients, whom 78 sustained during phase and were therefore eligible discontinue nilotinib phase; these, 53 (67.9%; 95% confidence interval: 56.4–78.1%) remained free...
Tyrosine kinase inhibitors (TKI) improve the prognosis of patients with chronic myelogenous leukemia (CML) by inducing substantial deep molecular responses (DMR); some have successfully discontinued TKI therapy after maintaining DMR for ≥1 year. In this cessation study, we investigated optimal conditions dasatinib discontinuation in who maintained ≥2 years. This study included 54 CML were enrolled a D-STOP multicenter prospective trial, had achieved DMR, and 2-year consolidation. Peripheral...
There is an increasing incidence of the evolution myelodysplastic syndrome (MDS) from aplastic anaemia (AA) with immunosuppressive treatment. In paediatric patients G‐CSF also reported to increase MDS evolution, but this process not precisely understood in children or adults. Therefore risk factors adults are evaluated here. Of 72 patients, five developed MDS. 47 without cyclosporine (CyA) antithymocyte globulin (ATG) therapy, only one trisomy 8, 242 months after diagnosis. But 25 treated...
To evaluate whether rescue with cord blood transplantation (CBT) could improve the poor survival after graft failure (GF), we surveyed data of 80 adult patients (median age, 51 years) who received CBT within 3 months GF (primary 64, secondary 16), fludarabine-based reduced-intensity regimens or without melphalan, busulfan, cyclophosphamide, and/or 2-4 Gy total-body irradiation (TBI). A median number 2.4 × 10(7)/kg total nucleated cells (TNC) were infused, and among 61 evaluable survived for...
Achievement of complete molecular response in patients with chronic phase myeloid leukemia has been recognized as an important milestone therapy cessation and treatment-free remission; the identification predictors these is, therefore, important. This study evaluated rates imatinib-treated major by using international standardization for quantitative polymerase chain reaction analysis breakpoint cluster region-Abelson1 gene. The correlation various clinical, pharmacokinetic, immunological...
The anti-CD38 antibody daratumumab (Dara) has been reported to improve the prognosis of multiple myeloma (MM) patients, but its use before autologous stem cell transplantation (ASCT) remains controversial. To clarify prognostic impact Dara ASCT on MM, we performed a retrospective observational analysis. We analyzed 2626 patients who underwent between 2017 and 2020. In comparison not administered (Dara- group) those (Dara+ group), 1-year progression-free survival (PFS) rates were 87.4% 77.3%...
Autologous stem cell transplantation (ASCT) is the standard of care for myeloma patients who achieve partial response (PR) or better after induction therapy. However, its clinical significance in with suboptimal (SR) before ASCT, including stable disease (SD) and progressive (PD), has not been established. Additionally, functional high-risk, SR early PD within 12 months, was a poor prognostic factor up to now. This study aimed evaluate efficacy ASCT novel agent era. multicenter retrospective...
Human T-cell lymphotropic virus type-1 (HTLV-1)-associated bronchioloalveolar disorder (HABA) is a specific state with chronic and progressive respiratory symptoms caused by bronchiolar or alveolar characterized smoldering adult leukemia the HTLV-I carrier state. We herein report rare case of HABA an initial presentation mosaic perfusion in lung. The diagnosis was made according to results flow cytometry analysis bronchoalveolar lavage fluid pathological findings. Clinicians must be careful...
Tandem autologous stem cell transplantation (ASCT) has been reconsidered for high-risk patients with myeloma, and the eligibility criteria up-front ASCT have updated to include more elderly patients. This study aimed evaluate efficacy tolerability of tandem in myeloma compared young single A retrospective using Transplant Registry Unified Management Program database Japanese Society Transplantation Cellular Therapy, which included 64 613 who received ASCT, 891 was conducted. The median...
The T cell-lineage marker CD2 is sometimes expressed in acute promyelocytic leukemia (APL), and expression reported to correlate with some clinical characteristics. However, the significance of APL has not been fully elucidated. We evaluated treated by same treatment strategy a single institute, whether it had any special Among 29 APL, 6 were positive for CD2. Patients CD2+ tended have higher leukocyte count than CD2- (34.5 +/- 13.1/l vs. 6.8 2.1/l), morphological characteristics as...